UP421

Phase 1Recruiting

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Type1diabetes

Conditions

Type1diabetes

Trial Timeline

Mar 8, 2024 → Jun 1, 2025

NCT ID

NCT06239636

About UP421

UP421 is a phase 1 stage product being developed by Sana Biotechnology for Type1diabetes. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06239636. Target conditions include Type1diabetes.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06239636	Phase 1	Recruiting	Mar 8, 2024	Jun 1, 2025	Type1diabetes

Competing Products

2 competing products in Type1diabetes

See all competitors

Product	Company	Stage	Hype Score
Dapagliflozin + Placebo Oral Tablet	AstraZeneca	Phase 1	29
XeriSol glucagon	Xeris Pharmaceuticals	Phase 1	23